Suppr超能文献

体外光化学疗法治疗系统性硬化症患者的长期随访初步结果。

Preliminary results on long-term follow-up of systemic sclerosis patients under extracorporeal photopheresis.

机构信息

Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

出版信息

J Dermatolog Treat. 2022 Jun;33(4):1979-1982. doi: 10.1080/09546634.2021.1925078. Epub 2021 Jul 29.

Abstract

BACKGROUND

Extracorporeal photopheresis (ECP) has been considered for treatment of patients with systemic sclerosis (SSc).

OBJECTIVES

To study the 12-month effects of ECP on laboratory parameters and evaluate the SSc-related long-term survival.

METHODS

59 SSc patients who had received at least 6 ECP cycles were included. Lab parameters were assessed at baseline (ECP naïve), after 6 months, and after 12 months. 20-year follow-up data were collected for all patients.

RESULTS

31 (59/52.5%) patients presented with elevated serum III procollagen (sPIIINP) levels at baseline which significantly declined after 6- and 12-month ECP. Total lymphocyte counts as well as circulating immune complexes (CICs) significantly decreased after 12-months ECP. On long-term follow-up, patients had received a median of 37.5 (6-167) ECP cycles over a median period of 64 (6-281) months. 20-year follow-up revealed only 8 (59/13.6%) SSc-related deaths and 51 (59/86.4%) survivors.

CONCLUSIONS

One-year ECP induces changes in lab parameters, such as sPIIINP, CICs, and lymphocyte counts, which have previously been implicated in the pathogenesis of SSc. More importantly, our data reveal, for the first time, that ECP-treated SSc patients appear to have extremely favorable 20-year survival rates compared to other SSc cohorts reported in the literature.

摘要

背景

体外光化学疗法(ECP)已被认为可用于治疗系统性硬化症(SSc)患者。

目的

研究 ECP 对实验室参数的 12 个月影响,并评估与 SSc 相关的长期存活率。

方法

纳入了 59 名至少接受 6 个 ECP 周期治疗的 SSc 患者。在基线(ECP 初治)、6 个月和 12 个月时评估实验室参数。对所有患者进行了 20 年的随访数据采集。

结果

31 名(59/52.5%)患者基线时血清 III 型前胶原(sPIIINP)水平升高,ECP 治疗 6 个月和 12 个月后显著下降。总淋巴细胞计数和循环免疫复合物(CIC)在 ECP 治疗 12 个月后显著减少。长期随访中,患者接受了中位数为 37.5(6-167)个 ECP 周期的中位数为 64(6-281)个月的治疗。20 年随访显示,仅 8 名(59/13.6%)患者与 SSc 相关死亡,51 名(59/86.4%)患者存活。

结论

一年的 ECP 可引起 sPIIINP、CIC 和淋巴细胞计数等实验室参数的变化,这些变化先前与 SSc 的发病机制有关。更重要的是,我们的数据首次表明,与文献中报道的其他 SSc 队列相比,ECP 治疗的 SSc 患者的 20 年生存率似乎极高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验